GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Madrigal Pharmaceuticals Inc (NAS:MDGL) » Definitions » Price-to-Tangible-Book

Madrigal Pharmaceuticals (Madrigal Pharmaceuticals) Price-to-Tangible-Book : 9.48 (As of Apr. 28, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Madrigal Pharmaceuticals Price-to-Tangible-Book?

As of today (2024-04-28), Madrigal Pharmaceuticals's share price is $193.33. Madrigal Pharmaceuticals's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $20.39. Hence, Madrigal Pharmaceuticals's Price to Tangible Book Ratio of today is 9.48.

The historical rank and industry rank for Madrigal Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:

MDGL' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.37   Med: 7.17   Max: 26.62
Current: 9.48

During the past 13 years, Madrigal Pharmaceuticals's highest Price to Tangible Book Ratio was 26.62. The lowest was 3.37. And the median was 7.17.

MDGL's Price-to-Tangible-Book is ranked worse than
87.79% of 1220 companies
in the Biotechnology industry
Industry Median: 2.65 vs MDGL: 9.48

A closely related ratio is called PB Ratio. As of today, Madrigal Pharmaceuticals's share price is $193.33. Madrigal Pharmaceuticals's Book Value per Sharefor the quarter that ended in Dec. 2023 was $20.39. Hence, Madrigal Pharmaceuticals's P/B Ratio of today is 9.48.


Madrigal Pharmaceuticals Price-to-Tangible-Book Historical Data

The historical data trend for Madrigal Pharmaceuticals's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Madrigal Pharmaceuticals Price-to-Tangible-Book Chart

Madrigal Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.37 7.18 7.39 26.62 11.35

Madrigal Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.62 29.50 41.20 121.40 11.35

Competitive Comparison of Madrigal Pharmaceuticals's Price-to-Tangible-Book

For the Biotechnology subindustry, Madrigal Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Madrigal Pharmaceuticals's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Madrigal Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Madrigal Pharmaceuticals's Price-to-Tangible-Book falls into.



Madrigal Pharmaceuticals Price-to-Tangible-Book Calculation

Madrigal Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2023 )
=193.33/20.394
=9.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Madrigal Pharmaceuticals Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Madrigal Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Madrigal Pharmaceuticals (Madrigal Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
Executives
Robert E. Waltermire officer: Senior VP, Chief Pharma Dev. FOUR TOWER BRIDGE, 200 BARR HARBOR DRIVE, SUITE 200, WEST CONSHOHOCKEN PA 19428
Baker Bros. Advisors Lp director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Brian Joseph Lynch officer: SVP and General Counsel 480 MORRIS ROAD, BLUE BELL PA 19422
William John Sibold director, officer: President and CEO C/O MADRIGAL PHARMACEUTICALS, INC., FOUR, TOWER BRIDGE, 200 BARR HARBOR DR STE 200, WEST CONSHOHOCKEN PA 19428
Felix Baker director BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Raymond Cheong director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker director BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Richard S Levy director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Remy Sukhija officer: SVP and Chief Comm'l Officer 48 PHEASANT HILL ROAD, PRINCETON NJ 08540
Alex G. Howarth officer: Chief Financial Officer C/O AKCEA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 9TH FLOOR, BOSTON MA 02210
Bay City Capital Llc 10 percent owner 750 BATTERY STREET STE 400, SAN FRANCISCO CA 94111
Fred B Craves director, 10 percent owner 750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111

Madrigal Pharmaceuticals (Madrigal Pharmaceuticals) Headlines